Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Clin Pharmacol. 2017 Nov 14;58(1):7–24. doi: 10.1002/jcph.1028

Figure 1.

Figure 1

Monoclonal antibody (mAb)-based targeted therapies can facilitate interactions between tumor cells and immune cells. Therapeutic mAbs can bind to growth factor receptors (such as members of the ErbB family of receptor tyrosine kinases). In addition to disrupting oncogenic signals emanating from these receptors, mAbs mediate interactions between tumor cells and immune cells (such as natural killer [NK] cells shown above). Cells such as NK cells can recognize the Fc regions of therapeutic mAbs via their Fcγ receptors. This can lead to antibody-dependent cellular cytotoxicity and tumor cell lysis.